Human Siglec-3/CD33 (Research Grade Gemtuzumab Biosimilar) Alexa Fluor™ Plus 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB9635AFP488
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry, CyTOF-ready
Label
Alexa Fluor Plus 488 (Excitation = 493 nm, Emission = 518 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Hu9a
Product Specifications
Specificity
Detects human Siglec‑3/CD33 based on Gemtuzumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Gemtuzumab. This product is for research use only.
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications
Application
Recommended Usage
CyTOF-ready
Optimal dilution of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilution of this antibody should be experimentally determined.
Background: Siglec-3/CD33
Long Name
Sialic Acid Binding Ig-like Lectin 3
Alternate Names
CD33, gp67, Siglec3
Gene Symbol
CD33
Additional Siglec-3/CD33 Products
Product Specific Notices
This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...